May 06, 2021

VIRALEZE™ launches in Europe (ASX Announcement)

VIRALEZE™ launches in Europe (ASX Announcement)

Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that VIRALEZE antiviral nasal spray is now available for purchase by consumers in Europe via Starpharma’s webstore.

VIRALEZE is already available in the UK through LloydsPharmacy’s 1,400 stores and online and is expected to be available via independent UK pharmacies later this month. 

VIRALEZE is a broad spectrum antiviral nasal spray that contains astodrimer sodium (SPL7013), which is virucidal, irreversibly inactivating >99.9% of coronavirus/SARS-CoV-2 within one minute[1]. These antiviral studies were conducted at the renowned Scripps Research Institute in the US and a number of other specialist virology laboratories.

The active in VIRALEZE (SPL7013) has demonstrated potent antiviral activity against multiple strains of SARS-CoV-2 as well as other respiratory viruses, including cold viruses, influenza, RSV (respiratory syncytial virus), MERS, and SARS.

The antiviral active in VIRALEZE (SPL7013) works by irreversibly blocking coronavirus SARS-CoV-2 ‘spike’ proteins from binding to human airway cells.

VIRALEZE antiviral nasal spray forms a physical barrier to respiratory viruses in the nasal cavity and has multiple unique advantages, including its virucidal action, its rapid onset (inactivates >99.9% SARS-CoV-2 within one minute, in laboratory studies1) and its ability to inactivate virus either before or after exposure1.

Dr Jackie Fairley, CEO of Starpharma commented: “We are delighted to be rolling out VIRALEZE in Europe following the UK launch. The product has been very well received in the UK, and we hope that VIRALEZE will provide European consumers with added peace of mind.”

“In addition to making VIRALEZE available direct to consumers in Europe via, commercial discussions for distribution continue in parallel. Starpharma is actively engaged in discussions with a variety of organisations in the region, including sporting teams, which have expressed interest in VIRALEZE.”

VIRALEZE is registered in the EU. Starpharma is pursuing avenues to provide rapid access to VIRALEZE™ in India, including opportunities for expedited registration and distribution in the region. The Company is also progressing regulatory activities for a number of markets, including Australia, with the intention to roll it out across multiple markets.

For more information on VIRALEZE visit

About VIRALEZE™ Antiviral Nasal Spray

VIRALEZE Antiviral Nasal Spray was developed by Starpharma (ASX: SPL) and is registered for sale in Europe. It is an easy-to-use antiviral nasal spray containing 1% w/w astodrimer sodium (SPL7013), shown in laboratory studies to inactivate respiratory viruses, including >99.9% of coronavirus SARS-CoV-2.

VIRALEZE binds to and irreversibly inactivates a broad spectrum of respiratory viruses. Inactivated viruses are blocked from attaching to cells inside your nose and taking hold. In addition to providing a protective antiviral barrier, VIRALEZE provides a moisturising layer to help keep nasal tissue hydrated, protecting it from dryness and damage.

SPL7013 is included in products that are already approved in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, South Africa, Australia, and New Zealand.

VIRALEZE can be used alongside vaccines, masks, and physical distancing.

 Advantages of VIRALEZE™

  • Broad-spectrum, works against multiple strains of SARS-CoV-2 and multiple respiratory viruses.
  • Potent antiviral activity against multiple strains of SARS-CoV-2.
  • Virucidal, irreversibly and rapidly inactivating >99.9% of coronavirus/ SARS‑CoV‑2 within one minute[1].
  • Ability to inactivate virus either before or after exposure.
  • Contains a well-tolerated, already marketed active, which is not absorbed into the bloodstream.
  • Provides a moisturising and protective barrier to help keep nasal tissue hydrated.
  • Room temperature storage, easy and convenient for regular use.

Starpharma acknowledges the $1 million in funding for the development of VIRALEZE™ provided by the Australian Government’s Medical Research Future Fund (MRFF) Biomedical Translation Bridge (BTB) Program, with support from UniQuest. Delivered by MTPConnect, the Australian Government's BTB program is a $22.3 million MRFF initiative that provides up to $1 million in matched funding to nurture the translation of new therapies, technologies and medical devices through to proof of concept to turn innovative medical ideas into reality.

[1] Paull, J.R.A. et al. Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro (2021). Antiviral Research:

 This contains certain forward-looking statements.